Summary
Unable to verify most statements against the provided FDA label excerpts. Several claims appear to be unsupported or not explicitly present in the supplied text, and many are broad/incorrectly framed (e.g., exercise-triggered blurred vision/dry mouth, “nerve areas” mechanism, arthritis/joint stress from weight gain, “controlled substance,” “24 hours” duration, alcohol/opioid/supplement interactions, and specific exercise safety guidance).
Category Scores
Accurate Statements
Lyrica (pregabalin) is used for seizures.
Section 1 Indications and Usage: “Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older.”
Lyrica is used for nerve pain.
Section 1 Indications and Usage includes neuropathic pain conditions (diabetic peripheral neuropathy, postherpetic neuralgia, neuropathic pain associated with spinal cord injury).
Lyrica can cause fluid retention.
Section 5.7 Peripheral Edema: “LYRICA treatment may cause peripheral edema.” (edema = fluid retention).
Dizziness or tiredness can occur right after taking a dose of Lyrica.
Section 6.1: “In the LYRICA treatment group, the adverse reactions most frequently leading to discontinuation were dizziness (4%) and somnolence (4%).” (timing not specified in excerpt).
Lyrica can cause swelling in the legs or feet.
Section 5.7 Peripheral Edema: “LYRICA treatment may cause peripheral edema.” (location not specified in excerpt).
Suddenly stopping Lyrica can produce withdrawal symptoms like insomnia.
Section 5.6: “Following abrupt or rapid discontinuation of LYRICA, some patients reported symptoms including insomnia…”
Suddenly stopping Lyrica can produce withdrawal symptoms like anxiety.
Section 5.6: “…anxiety…”
The label supports tapering Lyrica gradually rather than abruptly stopping.
Section 2.1: “When discontinuing LYRICA, taper gradually over a minimum of 1 week.” and Section 5.6: “If LYRICA is discontinued, taper the drug gradually over a minimum of 1 week rather than discontinue…abruptly.”
Lyrica may cause dizziness and somnolence.
Section 5.5: “LYRICA may cause dizziness and somnolence.”
Blurred vision can occur during or right after exercise with Lyrica.
Section 5.10: “reported blurred vision (7%) … resolved in a majority of cases…” (timing/exercise context not supported).
Unsupported Statements
Lyrica slows nerve signals.
Not stated in the provided excerpts.
Lyrica can make muscles feel weak or numb.
No muscle weakness/numbness claim is supported by the provided excerpts.
Lyrica can reduce coordination and balance.
No coordination/balance impairment claim is supported by the provided excerpts.
Reduced coordination and balance increase the chance of slips or falls while running or lifting.
No slips/falls linkage in the provided excerpts.
Blurred vision can occur during or right after exercise with Lyrica.
Blurred vision is mentioned, but exercise/timing context is not supported in the provided excerpts.
Dry mouth can occur during or right after exercise with Lyrica.
Dry mouth is not mentioned in the provided excerpts.
Dry mouth can lead to inadequate water intake during sessions.
No such counseling/mechanistic claim in the provided excerpts.
Inadequate water intake during sessions can lead to dehydration.
Not stated in the provided excerpts.
Slowed breathing can make intense cardio sessions cause more breathlessness than usual.
Respiratory depression is discussed, but breathlessness specifically during cardio is not supported in the provided excerpts.
Lyrica can slow breathing slightly.
Respiratory depression is discussed, but “slightly” is not supported.
Fluid retention keeps extra water in the nerve areas that the drug is targeted for.
No such mechanism is stated in the provided excerpts.
Lyrica can increase appetite in some people.
Weight gain is discussed, but increased appetite is not stated in the provided excerpts.
Extra weight adds stress to joints during squats, runs, or rowing.
No such functional/exercise-joint stress claim in the provided excerpts.
Weight gain of 5–10 pounds within months of starting Lyrica can result in slower progress in strength gains.
No pound range/time course nor “slower progress in strength gains” claim in the provided excerpts.
Lyrica is a controlled substance.
Controlled substance status is not stated in the provided excerpts.
Lyrica interacts with alcohol.
Additive cognitive/gross motor effects with ethanol are described, but the statement is too broad and not explicitly framed as an “interaction” in the provided excerpts.
Lyrica interacts with opioids.
Respiratory depression risk with CNS depressants including opioids is discussed, but the claim is incomplete and not tied to the label’s conditions (e.g., co-prescribing/underlying impairment/monitoring).
Mixing Lyrica with pre-workout supplements that contain stimulants can lead to irregular heart rhythms.
No stimulants/pre-workout or irregular heart rhythm claim is supported in the provided excerpts.
Mixing Lyrica with magnesium or amino acid supplements can amplify dizziness.
No magnesium/amino acid supplement claim is supported in the provided excerpts.
Lyrica stays active in the body for about 24 hours.
Pharmacokinetics excerpt states elimination half-life about 6 hours; “about 24 hours” is not supported.
The effects of Lyrica on balance and dizziness can persist into the morning hours after a previous dose.
Balance persistence is not stated; duration into the morning is not supported in the provided excerpts.
Next-day workouts requiring high coordination such as rock climbing or cycling may feel unsafe.
No rock climbing/cycling/high-coordination guidance is supported in the provided excerpts.
Contradictions
Low
AI Statement
Lyrica is a controlled substance.
Label Reference
Provided excerpts include no controlled-substance classification.
Important Omissions
When discontinuing Lyrica, taper gradually over a minimum of 1 week (and withdrawal symptoms list).
Importance:
Moderate
Renal-function-based dose adjustment because pregabalin is eliminated primarily by renal excretion.
Importance:
Moderate
CNS depressant/co-prescription monitoring for respiratory depression and sedation, especially with opioids or underlying respiratory impairment (and consider low starting dose).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Multiple statements provide exercise/supplement/timing or mechanistic guidance not supported by the provided label excerpts. While some safety topics are partially supported (dizziness/somnolence, peripheral edema, abrupt discontinuation symptoms, respiratory depression risk with CNS depressants), several unsupported claims could mislead users about specific causes, durations, and interaction types.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Unaligned
Primary Issue
Most user statements are not explicitly supported by the supplied FDA label excerpts, and several add specific timing/exercise/supplement/mechanism details not present in the label text.
Suggested Improvement
Restrict claims to label-supported content in the provided excerpts (e.g., approved indications; tapering/discontinuation guidance; dizziness/somnolence; peripheral edema; blurred vision; respiratory depression warnings with CNS depressants/monitoring; renal dose adjustment). Remove or qualify unsupported statements about supplements, controlled-substance status, exact duration (24 hours), exercise-specific effects, and detailed mechanisms not stated in the excerpts.